N
INZY

Nuveen’s Inozyme Pharma INZY Stock Holding History

Nuveen’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-160,879
Closed -$146K – 3328
2025
Q1 		$146K Sell
160,879
-89,350
-36% -$124K ﹤0.01% 3169
2024
Q4 		$693K Buy
250,229
+47,500
+23% +$181K ﹤0.01% 2862
2024
Q3 		$1.06M Buy
202,729
+41,850
+26% +$217K ﹤0.01% 2736
2024
Q2 		$718K Hold
160,879
– – ﹤0.01% 2860
2024
Q1 		$1.23M Hold
160,879
– – ﹤0.01% 2617
2023
Q4 		$685K Buy
160,879
+23,130
+17% +$82.2K ﹤0.01% 2895
2023
Q3 		$579K Hold
137,749
– – ﹤0.01% 2797
2023
Q2 		$767K Buy
+137,749
New +$814K ﹤0.01% 2772
2022
Q2 		– Sell
-43,574
Closed -$172K – 3371
2022
Q1 		$172K Buy
43,574
+1,313
+3% +$7.73K ﹤0.01% 3213
2021
Q4 		$251K Sell
42,261
-5,401
-11% -$46.6K ﹤0.01% 3202
2021
Q3 		$565K Buy
47,662
+268
+0.6% +$4.18K ﹤0.01% 3146
2021
Q2 		$808K Buy
47,394
+26,102
+123% +$454K ﹤0.01% 3080
2021
Q1 		$422K Hold
21,292
– – ﹤0.01% 3123
2020
Q4 		$439K Buy
21,292
+4,222
+25% +$101K ﹤0.01% 3069
2020
Q3 		$449K Buy
+17,070
New +$424K ﹤0.01% 2982

Other funds holding INZY

BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Nuveen's INZY Position: Q2 2025 in Review

Nuveen sold out of Inozyme Pharma (INZY) in Q2 2025, closing a stake of 160,879 shares — an estimated $146K sold.

Nuveen first reported a position in INZY in Q3 2020 and held it in 15 quarters. The position peaked at $1.23M in Q1 2024. 86 funds tracked by Wall St. Rank hold INZY as of Q2 2025.

  • Nuveen reported no remaining Inozyme Pharma position as of Q2 2025 after selling out during the quarter.
  • Nuveen sold 160,879 Inozyme Pharma shares in Q2 2025, an estimated $146K.
  • Nuveen first reported a position in Inozyme Pharma in Q3 2020 and held it in 15 quarters.
  • Nuveen's Inozyme Pharma position peaked at $1.23M in Q1 2024.
  • 86 funds tracked by Wall St. Rank held Inozyme Pharma as of Q2 2025.

Based on Nuveen's 13F filing for Q2 2025, filed 12 Aug 2025.